Skip to main content
Clinical Trials/NCT02535520
NCT02535520CompletedNot Applicable

Clinical Evaluation of RTVue XR With SSADA in Retinal Patients

Optovue0 sites155 target enrollmentStarted: August 2015Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Sponsor
Enrollment
155
Primary Endpoint
Agreement of SSADA to conventional angiography

Study Overview

Brief Summary

Optovue has implemented a motion contrast imaging software in RTVue XR, a split spectrum amplitude decorrelation algorithm (SSADA), for non-invasive imaging of ocular vasculature. Consented subjects will undergo a series of images of the back of the eye using an Optical Coherence Tomograpy (OCT) device, RTVue XR, in addition to the conventional images as part of clinical routine. SSADA images will be compared with conventional methods.

Study Design

Study Type
Observational
Observational Model
Case Only
Time Perspective
Prospective

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Able and willing to complete exams
  • •Patients in retina clinic that need angiography

Exclusion Criteria

  • •Unable to complete the required examinations and visits
  • •Large amount of subretinal hemorrhage
  • •Media opacity leading to poor quality images
  • •Extreme refractive error leading to poor quality images
  • •Pathologies in the anterior segment leading to poor quality images

Outcomes

Primary Outcomes

Agreement of SSADA to conventional angiography

Time Frame: Day 1

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor
Optovue
Sponsor Class
Industry
Responsible Party
Sponsor

Similar Trials